Results 11 to 20 of about 471 (127)

Mechanistic basis for inhibition of the extended-spectrum β-lactamase GES-1 by enmetazobactam and tazobactam. [PDF]

open access: yesFEBS Lett
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Beer M   +10 more
europepmc   +5 more sources

Evaluation of the Activity of Cefepime/Enmetazobactam Against Enterobacterales Bacteria Collected in Europe From 2019 to 2021, Including Third-Generation Cephalosporin-Resistant Isolates

open access: yesJournal of Global Antimicrobial Resistance
: Objectives: This study was performed to investigate the activity of the novel ß-lactam/ß-lactamase inhibitor combination cefepime/enmetazobactam, against recently circulating Enterobacterales isolates from Europe from 2019 to 2021. Methods: A total of
Stephen Hawser   +2 more
exaly   +4 more sources

In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae [PDF]

open access: yesMicrobiology Spectrum
Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar
S. Albac   +6 more
doaj   +3 more sources

Cefepime/Enmetazobactam for Gram-Negative Periprosthetic Joint Infections? A Randomized Porcine Study on Target Tissue Pharmacokinetics [PDF]

open access: yesJournal of Antimicrobial Chemotherapy
Abstract Background Periprosthetic joint infections pose clinical and socioeconomic challenges. Gram-negative pathogens are associated with poorer outcomes compared with Gram-positive organisms. Rising antimicrobial resistance limits treatment options.
Alex Soriano, Christoph Crocoll
exaly   +8 more sources

Cefepime-Enmetazobactam: First Approved Cefepime-β- Lactamase Inhibitor Combination for Multi-Drug Resistant Enterobacterales [PDF]

open access: yesFuture Microbiology
Cefepime-enmetazobactam is a β-lactam/β-lactamase inhibitor (BL/BLI) combination that has demonstrated potent activity against extended spectrum beta-lactamase (ESBL)-producing Enterobacterales, recently approved by the US FDA for the treatment of complicated urinary tract infections (cUTI) and by the European Medicines Agency and the UK Healthcare ...
Tanaya Bhowmick   +2 more
exaly   +6 more sources

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics [PDF]

open access: yesPathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou   +4 more
doaj   +3 more sources

Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations [PDF]

open access: yesInfection and Drug Resistance
Milo Gatti,1,2 Federico Pea1,2 1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItalyCorrespondence ...
Gatti M, Pea F
doaj   +3 more sources

Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula [PDF]

open access: yesScientific Reports
This study investigated the in vitro antimicrobial activity of cephamycins and novel β-lactam/β-lactamase inhibitor combinations, against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates.
Yu Mi Wi   +5 more
doaj   +3 more sources

CEFEPIME/ENMETAZOBACTAM: Physicochemical Stability of a Novel β-Lactam/β-Lactamase Inhibitor Combination in Syringes and Elastomeric Devices [PDF]

open access: yesAntibiotics
Background: Cefepime/enmetazobactam (FEP/META) is a novel fixed-dose β-lactam/β-lactamase inhibitor combination. The objective was to study the physicochemical stability of the approved daily dose in polypropylene syringes and elastomeric devices over a ...
Akim Chayem   +9 more
doaj   +4 more sources

Penicillanic Acid Sulfones Inactivate the Extended-Spectrum β-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of β-Lactamase Inhibition [PDF]

open access: yesmBio, 2022
β-Lactamases hydrolyze β-lactam antibiotics and are major determinants of antibiotic resistance in Gram-negative pathogens. Enmetazobactam (formerly AAI101) and tazobactam are penicillanic acid sulfone (PAS) β-lactamase inhibitors that differ by an ...
Philip Hinchliffe   +10 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy